ClinicalTrials.gg
Active, not recruitingNCT03914794Updated Nov 16, 2026Results posted

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

A Phase 2 interventional study of Pemigatinib in Bladder Cancer, NMIBC and Non-Muscle Invasive Bladder Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: Urinary Bladder NeoplasmsReclassifiedWhy we changed it
Registry
Urinary Bladder Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Urinary Bladder Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now Active, not recruitingResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Enrollment
62nd of 93
30 · median 55
Started
2020
with 5 others
Phase 2
20 of 114
8 open now
Primary completion
2025-09
later than 6 of 59 live
Registered
38th of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 62nd largest by enrollment of the 93 interventional ones that give a count, is one of 6 that started in 2020, is one of 20 in phase 2, reaches primary completion later than 6 of the 59 other live ones, and was the 38th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).

Read the detailed description

It is a single-arm phase 2 window of opportunity study to assess the antineoplastic activity of pemigatinib in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Enrolled patients will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT). The primary endpoint will be complete response rate as determined at TURBT. Secondary endpoints will include safety profile, associations between complete response rate and tumor mutation/fusion status (e.g. FGFR3 specifically, others will also be examined) and NMIBC risk group (low- vs. intermediate-risk), and assessment of pemigatinib post-treatment urothelial tissue concentrations. The study will be conducted at 4-5 high volume bladder cancer institutions within the US and managed through the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center clinical research office.

03

Conditions studied

  • Bladder Cancer
  • NMIBC
  • Non-Muscle Invasive Bladder Cancer
  • Urothelial Carcinoma Recurrent

Keywords

  • Bladder Cancer
  • Non Muscle Invasive Bladder Cancer
  • Non-Muscle Invasive Bladder Cancer (NMIBC)
  • NMIBC
  • Urothelial Carcinoma
  • Urothelial Cancer
  • Urinary Bladder Neoplasm
  • Bladder Neoplasm
  • Fibroblast inhibitors
  • Pemigatinib
  • FGFR inhibitor
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

This study's enrollment of 30 is below the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor of 582 studies on the registry; 71 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 68 (60%) have results posted.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior confirmed low- or intermediate-risk non-muscle invasive urothelial carcinoma of the bladder (NMIBC) defined according to the following characteristics:

    • Low Risk

      • Initial tumor with all of the following:
      • Solitary tumor
      • Ta tumor
      • Low-grade
      • \<3 cm
      • No CIS
    • Intermediate Risk

      --- All tumors not defined in the two adjacent categories (between the category of low- and high-risk)

    • High Risk

      • T1 tumor
      • High-grade
      • CIS
      • Multiple and recurrent and large (>3 cm) Ta low-grade tumors (all conditions must be met for this point on Ta low-grade tumors)
  • Documented tumor recurrence as noted in standard of care follow up cystoscopy.
  • (WHO) performance status 0-2
  • Age ≥ 18 years old
  • Patients must have the following laboratory values:

    • White blood cell count (WBC) > 3.0 K/mm3
    • (ANC) ≥ 1.5 K/mm3
    • ≥ 100 K/mm3
    • (Hgb) ≥ 9 g/dL
    • Serum total : ≤ 1.5 x
    • and AST ≤ 3.0 x ULN
    • Serum calcium \< ULN
    • Serum phosphate \< ULN
    • Serum creatinine ≤ 1.5 x ULN or serum creatinine > 1.5 - 3 x ULN if calculated (CrCl) is ≥ 30 mL/min using the modified Cockcroft-Gault equation
  • Patients who give a written obtained according to local guidelines

Exclusion criteria

Exclusion Criteria:

  • Patients with concurrent upper urinary tract (i.e. ureter, renal pelvis) non-invasive urothelial carcinoma.
  • Patients with high grade urothelial carcinoma on their most recent urine cytology.
  • Patients with another active second other than non-melanoma skin cancers and biochemical prostate cancer. (Patients that have completed all necessary therapy and are considered to be at less than 30% risk of relapse are not considered to have an active second malignancy and are eligible for enrollment.)
  • Patients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies ≤ 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
  • Patients who have received prior selective fibroblast growth factor receptor targeting agents (i.e. pemigatinib, dovitinib, BGJ398, AZD4547, JNJ-42756493, etc.).
  • Patients who have had radiotherapy ≤ 4 weeks prior to starting study drug, or who have not recovered from radiotherapy toxicities
  • Patients who have undergone major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic), open or significant traumatic injury ≤ 4 weeks prior to starting study drug, or patients who have had minor procedures (i.e. TURBT), percutaneous biopsies or placement of vascular access device ≤ 1 week prior to starting study drug, or who have not recovered from side effects of such procedure or injury
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment: Pemigatinib

    Patients will receive pemigatinib for 4 to 6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).

    Drug: Pemigatinib

Interventions

  • Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.

    Also known as: INCB054828, FGFR inhibitor INCB054828

07

What researchers measure

Primary outcomes

  1. Complete Response Rate of Pemigatinib Therapy

    The number of participants with a complete response to pemigatinib therapy. Tumor complete response is defined as the complete absence of any stage bladder tumor on post-treatment Transurethral Resection of a Bladder Tumor (TURBT) and no evidence of recurrent urothelial carcinoma on post-treatment urine cytology.

    Time frame: 6 weeks

Secondary outcomes

  1. Characterize the Safety Profile of Pemigatinib Therapy

    Number of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 toxicities

    Time frame: 4 years

  2. Number of Participants With Complete Response and FGFR3 Mutational Status

    Time frame: Up to 4 weeks

  3. Number of Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Complete Response

    Number of participants with complete response rate and baseline NMIBC risk group (low- vs. intermediate-risk)

    Time frame: Up to 4 years

  4. Relapse Free Survival (RFS) at 6 Months

    Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first.

    Time frame: 6 months

  5. Relapse Free Survival (RFS) at 12 Months

    Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first.

    Time frame: 12 months

  6. Relapse Free Survival (RFS) at 24 Months

    Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first.

    Time frame: 24 months

08

Results

Posted Nov 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment: Pemigatinib
Started30
Completed30
Not completed0

Outcome measures

PrimaryComplete Response Rate of Pemigatinib Therapy

The number of participants with a complete response to pemigatinib therapy. Tumor complete response is defined as the complete absence of any stage bladder tumor on post-treatment Transurethral Resection of a Bladder Tumor (TURBT) and no evidence of recurrent urothelial carcinoma on post-treatment urine cytology.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Complete Response Rate of Pemigatinib Therapy
ParticipantsTreatment: Pemigatinib
Complete Response Rate of Pemigatinib Therapy16
SecondaryCharacterize the Safety Profile of Pemigatinib Therapy

Number of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 toxicities

Time frame:
4 years
Reported as:
Number · Adverse Events
Characterize the Safety Profile of Pemigatinib Therapy
Adverse EventsTreatment: Pemigatinib
Characterize the Safety Profile of Pemigatinib Therapy5
SecondaryNumber of Participants With Complete Response and FGFR3 Mutational Status
Time frame:
Up to 4 weeks

Results for this outcome have not been posted.

SecondaryNumber of Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Complete Response

Number of participants with complete response rate and baseline NMIBC risk group (low- vs. intermediate-risk)

Time frame:
Up to 4 years

Results for this outcome have not been posted.

SecondaryRelapse Free Survival (RFS) at 6 Months

Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first.

Time frame:
6 months
Reported as:
Number · percentage
Relapse Free Survival (RFS) at 6 Months
percentageTreatment: Pemigatinib
Relapse Free Survival (RFS) at 6 Months86 (74 to 100)
SecondaryRelapse Free Survival (RFS) at 12 Months

Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first.

Time frame:
12 months
Reported as:
Number · percentage
Relapse Free Survival (RFS) at 12 Months
percentageTreatment: Pemigatinib
Relapse Free Survival (RFS) at 12 Months75 (61 to 93)
SecondaryRelapse Free Survival (RFS) at 24 Months

Relapse-free survival (RFS) is defined as the duration of from the on study date to time of first documented bladder tumor of any stage or grade, progression or death, whichever occurs first.

Time frame:
24 months
Reported as:
Number · percentage
Relapse Free Survival (RFS) at 24 Months
percentageTreatment: Pemigatinib
Relapse Free Survival (RFS) at 24 Months70 (55 to 90)

Adverse events

Collected over From the start of treatment until 30 days post the last study treatment, an average of 4.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment: Pemigatinib0/30 (0%)1/30 (3.3%)29/30 (96.7%)
Most frequent serious events
Most frequent serious events
EventTreatment: Pemigatinib
Vitreomacular Traction Separation of the retinal layersEye disorders1/30
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTreatment: Pemigatinib
Dry mouthGastrointestinal disorders18/30
AlopeciaSkin and subcutaneous tissue disorders13/30
DiarrheaGastrointestinal disorders13/30
FatigueGeneral disorders13/30
DysgeusiaNervous system disorders12/30
Dry eyeEye disorders9/30
ConstipationGastrointestinal disorders8/30
HyperphosphatemiaMetabolism and nutrition disorders6/30
Dry skinSkin and subcutaneous tissue disorders5/30
NauseaGastrointestinal disorders5/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment: Pemigatinib
Median75.5 (69.2 to 80.8)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment: Pemigatinib
Female8
Male22
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment: Pemigatinib
Hispanic or Latino2
Not Hispanic or Latino28
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment: Pemigatinib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White24
More than one race0
Unknown or Not Reported3
09

Study locations

6 sites
  • Sibley Memorial Hospital
    Washington D.C., District of Columbia 20016, United States
  • Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21205, United States
  • Associated Medical Professionals Urology
    Syracuse, New York 13210, United States
  • Midlantic Urology
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Keystone Urology
    Lancaster, Pennsylvania 17604, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2020 to primary completion in Sep 2025, 59 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2025 → Jul 2027, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2019
First posted
Apr 16, 2019
StartActual
Oct 2, 2020
Primary completionActual
Sep 30, 2025
CompletionEst.
Jul 1, 2027was Sep 2025
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Active, not recruiting
changed Nov 16, 2026
Results
Results posted
posted Nov 16, 2026
Study completion
Sep 30, 2025→Jul 1, 2027
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedComplete response rateResponse Rate of pemigatinib therapyPemigatinib TherapyTime frame: 6 weeks
Nov 16, 2026
Secondary outcomes
6 edited, 1 removed
What changed in the outcomes
  • EditedCharacterize the safety profileSafety Profile of pemigatinib therapyPemigatinib TherapyTime frame: 4 years
  • EditedNumber of Participants withWith Complete Response and FGFR3 Mutational StatusTime frame: Up to 4 weeks
  • EditedNumber of Participants withWith Non-Muscle Invasive Bladder Cancer (NMIBC) and Complete ResponseTime frame: Up to 4 years
  • EditedRelapse Free Survival (RFS) at 6 monthsMonthsTime frame: 6 months
  • EditedRelapse Free Survival (RFS) at 12 monthsMonthsTime frame: 12 months
  • EditedRelapse Free Survival (RFS) at 24 monthsMonthsTime frame: 24 months
  • RemovedMaximal concentration (Cmax, nmol/L) of pemigatinib in urothelial tissue at post-treatment TURBTTime frame: Up to 4 weeks
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Completed→Active, not recruiting
    Results posted
    Study completion Sep 30, 2025→Jul 1, 2027
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedComplete response rateResponse Rate of pemigatinib therapyPemigatinib TherapyTime frame: 6 weeks
    Secondary outcomes 6 edited, 1 removed
    What changed in the outcomes
    • EditedCharacterize the safety profileSafety Profile of pemigatinib therapyPemigatinib TherapyTime frame: 4 years
    • EditedNumber of Participants withWith Complete Response and FGFR3 Mutational StatusTime frame: Up to 4 weeks
    • EditedNumber of Participants withWith Non-Muscle Invasive Bladder Cancer (NMIBC) and Complete ResponseTime frame: Up to 4 years
    • EditedRelapse Free Survival (RFS) at 6 monthsMonthsTime frame: 6 months
    • EditedRelapse Free Survival (RFS) at 12 monthsMonthsTime frame: 12 months
    • EditedRelapse Free Survival (RFS) at 24 monthsMonthsTime frame: 24 months
    • RemovedMaximal concentration (Cmax, nmol/L) of pemigatinib in urothelial tissue at post-treatment TURBTTime frame: Up to 4 weeks
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT03914794
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Oct 2, 2020
Primary completion
Sep 30, 2025
Completion
Jul 1, 2027 (estimated)
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Noah M Hahn, MD
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion